

# 8<sup>th</sup> International Symposium



## Advanced Ovarian Cancer: OPTIMAL Therapy. Update

Valencia, Spain, 4<sup>th</sup> March 2011

### venue

Palau de la Música  
Rodrigo Meeting Room  
Paseo de la Alameda, 30  
46030 Valencia (Spain)

### language

The official language of the Symposium is English.  
Simultaneous translation into Spanish will be provided.

### credits

Accredited by the European Society for Medical Oncology Educational Committee for its medical oncology certification approval program with **8 ESMO MORA category 1 points**.



Actividad acreditada en base a la encomienda de gestión concedida por los Ministerios de Sanidad y Política Social y Ministerio de Educación al Consejo General de Colegios Oficiales de Médicos (*Resolución de 22 de marzo de 2002, BOE Núm. 81 de 4 de abril de 2002*) con **1,1 CRÉDITOS** equivalente a **8 horas lectivas**.



Credits acknowledged by the European Accreditation Council for Continuing Medical Education (EACCME), *Union Européenne des Médecins Spécialistes* (UEMS, European Union of Medical Specialists).

### SYMPOSIUM SECRETARIAT

Doctaforum  
Tel.: +34 91 372 0203  
Fax: +34 91 735 0454  
E-mail: aocsymp2011@doctaforum.com  
www.doctaforum.com/aocsymp

### organized by



### under the AUSPICES OF



### Organized by:



### DIRECTORS

Andrés Poveda  
*Fundación Instituto Valenciano de Oncología, Valencia, Spain*

Jan B. Vermorken  
*Antwerp University Hospital, Edegem, Belgium*

[doctaforum.com/aocsymp](http://doctaforum.com/aocsymp)

### Scientific committee

Andrés Cervantes (ESMO, GEICO)  
Antonio González (ESMO, GEICO)  
Jan B. Vermorken (ESMO)  
Andrés Poveda (ESMO, GEICO)

# SCIENTIFIC PROGRAM

08:30	<p><b>Welcome</b>  <b>David Kerr</b>          ESMO President</p> <p><b>Manuel Llombart</b>          General Manager, Fundación Instituto Valenciano de Oncología, Valencia, Spain</p>
08:45-09:25	<p><b>Keynote Lecture: Molecular Biology In Ovarian Cancer</b>  <b>Robert C. Bast Jr</b>          The University of Texas, MD Anderson Cancer Center, Houston (Texas), USA</p>

## SESSION-1 EARLY DETECTION

CHAIRS:	<p><b>Elise C. Kohn</b>          National Cancer Institute, Bethesda (Maryland), USA</p> <p><b>Andrés Cervantes</b>          Hospital Clínico Universitario, Valencia, Spain</p>
09:25-09:45	<p><b>Defining the Target for Early Detection</b>  <b>Patrick O. Brown</b>          Stanford University School of Medicine, Stanford (California), USA</p>
09:45-10:05	<p><b>Designing Early Detection Programs for Ovarian Cancer</b>  <b>Nicole Urban</b>          Fred Hutchinson Cancer Research Center, Seattle (Washington), USA</p>
10:05-10:20	<p><b>Discussion</b></p>

## SESSION-2 PRIMARY OVARIAN CANCER - PART-1

CHAIRS:	<p><b>Jonathan Berek</b>          Stanford University School of Medicine, Stanford (California), USA</p> <p><b>Sergi Martínez</b>          Hospital Clínic, Barcelona, Spain</p>
10:20-10:40	<p><b>Quality Control in Ovarian Cancer Surgery</b>  <b>Neville F. Hacker</b>          Royal Hospital for Women, Randwick, Australia</p>
10:40-11:00	<p><b>Is the use of PET/CT Leading to Stage Migration?</b>  <b>Svend A. Engelholm</b>          Copenhagen University Hospital, Copenhagen, Denmark</p>
11:00-11:20	<p><b>Preoperative Serum CA125 Levels and Risk of Suboptimal Cytoreduction in Ovarian Cancer</b>  <b>Sang-Yoon Park</b>          Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Ilsan-gu Madu-dong, Goyang, Republic of Korea</p>
11:20-11:30	<p><b>Discussion</b></p>
11:30-12:00	<p><b>Coffee break</b></p>

## SESSION-3 PRIMARY OVARIAN CANCER - PART2

CHAIRS:	<p><b>Nicoletta Colombo</b>          European Institute of Oncology, Milan, Italy</p> <p><b>Jan B. Vermorken</b>          Antwerp University Hospital, Edegem, Belgium</p>
12:00-12:45	<p><b>Dose Dense Therapy is of Benefit in Primary Treatment of Ovarian Cancer?</b></p> <p><b>PRO:</b> <b>Noriyuki Katsumata</b>          National Cancer Center Hospital, Tokyo, Japan</p> <p><b>CON:</b> <b>Maria EL van der Burg</b>          Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands</p> <p><b>Discussion</b></p>
12:45-13:30	<p><b>Follow up with CA125 After Primary Therapy of Advanced Ovarian Cancer has Major Implications for Treatment Outcome and Trial Performances</b></p> <p><b>PRO:</b> <b>Sandro Pignata</b>          National Cancer Institute Fondazione Pascale, Naples, Italy</p> <p><b>CON:</b> <b>Gordon Rustin</b>          Mount Vernon Cancer Center, Northwood (Middlesex), United Kingdom</p> <p><b>Discussion</b></p>
13:30-14:55	<p><b>Lunch</b></p>

## SESSION-4 RANDOMIZED TRIALS IN OVARIAN CANCER

CHAIRS:	<p><b>Bradley J. Monk</b>          Comprehensive Cancer Center, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Phoenix (Arizona), USA</p> <p><b>Sandro Pignata</b>          National Cancer Institute Fondazione Pascale, Naples, Italy</p>
15:00-15:20	<p><b>Optimal Assessment of Response in Ovarian Cancer (Recist 1.1 Criteria, CA125...)</b>  <b>Elizabeth Eisenhauer</b>          NCIC Clinical Trials Group, Kingston (Ontario), Canada</p>
15:20-15:45	<p><b>Update of Randomized Trials in First Line</b>  <b>Michael Bookman</b>          Arizona Cancer Center, Tucson (Arizona), USA</p>
15:45-16:10	<p><b>Update of Randomized Trials in Recurrent Disease</b>  <b>Eric Pujade-Lauraine</b>          Hôpital Hôtel-Dieu, Paris, France</p>
16:10-16:30	<p><b>Report of the 4th OCCC</b>  <b>Gavin Stuart</b> (on behalf of GCIG)</p>
16:30-17:00	<p><b>Discussion</b></p>
17:00-17:30	<p><b>Coffee break</b></p>

## SESSION-5 NEW THERAPIES IN OVARIAN CANCER

CHAIRS:	<p><b>Stanley B. Kaye</b>          The Royal Marsden Hospital, London, United Kingdom</p> <p><b>Antonio González-Martín</b>          Centro Oncológico MD Anderson International España, Madrid, Spain</p>
17:30-18:10	<p><b>Antiangiogenic Therapy</b></p> <p><b>PRO:</b> <b>Robert A. Burger</b>          Fox Chase Cancer Center, Philadelphia (Pennsylvania), USA</p> <p><b>CON:</b> <b>Maurie Markman</b>          Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia (Pennsylvania), USA</p> <p><b>Discussion</b></p>
18:10-18:25	<p><b>Parp Inhibition</b>  <b>Cristiana Sessa</b>          Ospedale San Giovanni, Bellinzona, Switzerland</p>
18:25-18:45	<p><b>Other New Therapies</b>  <b>David R. Spriggs</b>          Memorial Sloan-Kettering Cancer Center, New York (New York), USA</p>
18:45-19:00	<p><b>Discussion</b></p>
19:00-19:15	<p><b>Remarks and Conclusions</b>  <b>Andrés Poveda</b>          Fundación Instituto Valenciano de Oncología, Valencia, Spain</p>